Discover 298 paid clinical trials in Idaho. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Idaho provides a wide range of paid clinical research opportunities for both healthy volunteers and people with specific health conditions. Facilities in Boise, Idaho Falls, and Meridian are actively seeking participants, offering access to new therapies and specialized care.
Filter
1
Filter results
Results: 298
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
for
Acute Myeloid Leukemia
Location: Halifax, Portland ME, Scarborough ME, South Portland ME,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 59
Code: NCT05554393
Phase 2, Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
for
Triple Negative Breast Cancer
Location: Scarborough ME, South Weymouth MA, Boston MA,
Sponsor: Gilead Sciences
Sex: All
Age: 18+
Code: NCT05633654
Phase 3, Recruiting
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
for
Migraine
Location: The Bronx NY, Washington D.C. DC, Tamarac FL,
Sponsor: Pfizer
Sex: All
Age: 6 - 17
Code: NCT05156398
Phase 3, Recruiting
Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
Location: Chicago IL, Minneapolis MN, Spokane WA, Boise ID,
Sponsor: Seattle Institute for Biomedical and Clinical Research
Sex: All
Age: 18+
Code: NCT06390345
Recruiting
Effectiveness of Aurix Therapy in Venous Leg Ulcers
for
Venous Leg Ulcers
Location: Boston MA, Bristol CT, Middletown NY, Harris NY,
Sponsor: Nuo Therapeutics
Sex: All
Age: 18+
Code: NCT02352454
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
for
Non-squamous Non-small Cell Lung Cancer
Location: Saint John, South Portland ME, West Haven CT,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06627647
Phase 3, Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer